Chong Zhi-Xiong
Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500 Semenyih, Selangor, Malaysia; NUS Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Centre for Translational Medicine, 14 Medical Drive, #12-01, Singapore 117599; Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, 14 Medical Drive, #12-01, Singapore 117599.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189191. doi: 10.1016/j.bbcan.2024.189191. Epub 2024 Sep 29.
Ovarian cancer is one of the gynaecology malignancies with the highest mortality rate. Ovarian cancer stem cell (CSC) is a subpopulation of ovarian cancer cells with increased self-renewability, aggression, metastatic potentials, and resistance to conventional anti-cancer therapy. The emergence of ovarian CSC is a critical factor that promotes treatment resistance and frequent relapse among ovarian cancer patients, leading to poor clinical outcomes. MicroRNA (miRNA) is a short, non-protein-coding RNA that regulates ovarian CSC development. Although multiple original research articles have discussed the CSC-regulatory roles of different miRNAs in ovarian cancer, there is a deficiency of a review article that can summarize the findings from different research papers. To narrow the gap in the literature, this review aimed to provide an up-to-date summary of the CSC-regulatory roles of various miRNAs in modulating ovarian cancer cell stemness. This review will begin by giving an overview of ovarian CSC and the pathways responsible for driving its appearance. Next, the CSC-regulatory roles of miRNAs in controlling ovarian CSC development will be discussed. Overall, more than 60 miRNAs have been reported to play CSC-regulatory roles in the development and progression of ovarian cancer. By targeting various downstream targets, these miRNAs can control the signaling activities of PI3K/AKT, EGFR/ERK, WNT/ß-catenin, NF-kß, Notch, Hippo/YAP, EMT, and DNA repair pathways. Hence, these CSC-modulatory miRNAs have the potential to be used as prognostic biomarkers in predicting the clinical outcomes of ovarian cancer patients. Targeting CSC-promoting miRNAs or increasing the expressions of CSC-repressing miRNAs can help slow ovarian cancer progression. However, more in-depth functional and clinical trials must be carried out to evaluate the suitability, safety, sensitivity, and specificity of these CSC-regulating miRNAs as prognostic biomarkers or therapeutic targets.
卵巢癌是死亡率最高的妇科恶性肿瘤之一。卵巢癌干细胞(CSC)是卵巢癌细胞中的一个亚群,具有增强的自我更新能力、侵袭性、转移潜能以及对传统抗癌治疗的抗性。卵巢CSC的出现是导致卵巢癌患者治疗抗性和频繁复发的关键因素,从而导致临床预后不良。微小RNA(miRNA)是一种短的非蛋白质编码RNA,可调节卵巢CSC的发育。尽管多篇原创研究文章讨论了不同miRNA在卵巢癌中对CSC的调控作用,但缺乏一篇能够总结不同研究论文结果的综述文章。为了缩小文献中的差距,本综述旨在提供关于各种miRNA在调节卵巢癌细胞干性方面对CSC调控作用的最新总结。本综述将首先概述卵巢CSC以及导致其出现的相关通路。接下来,将讨论miRNA在控制卵巢CSC发育方面的CSC调控作用。总体而言,已有超过60种miRNA被报道在卵巢癌的发生和发展中发挥CSC调控作用。通过靶向各种下游靶点,这些miRNA可以控制PI3K/AKT、EGFR/ERK、WNT/β-连环蛋白、NF-κB、Notch、Hippo/YAP、EMT和DNA修复通路的信号活性。因此,这些调节CSC的miRNA有潜力作为预测卵巢癌患者临床预后的预后生物标志物。靶向促进CSC的miRNA或增加抑制CSC的miRNA的表达有助于减缓卵巢癌的进展。然而,必须进行更深入的功能和临床试验,以评估这些调节CSC的miRNA作为预后生物标志物或治疗靶点的适用性、安全性、敏感性和特异性。